Investigating the effect of glutamine supplementation on the Rectus Femoris and Vastus Intermedius mascles thinckness in patients undergoing laparoscopic sleeve gastrectomy

Start Date20 Jan 2025

Sponsor / Collaborator

Shahid Beheshti University of Medical Sciences

IRCT20200929048876N4 / SuspendedNot ApplicableIIT

Evaluation the effect of glutamine on inflammation and infectious events in patients with mild burns involving under 20% of the body area

Start Date21 Oct 2024

Sponsor / Collaborator

Zanjan University of Medical Sciences

NCT06617182 / Not yet recruitingPhase 2IIT

Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury: a Single-center, Open-label, Randomized Controlled Study

At present, there is still a lack of standard and effective treatment strategies and procedures for radiation intestinal injury. Studies have shown that thalidomide can effectively treat refractory gastrointestinal bleeding caused by vascular malformation. Therefore, The investigators designed a single-center, open-label, randomized controlled study to evaluate the efficacy and safety of thalidomide combined with glutamine in the treatment of radiation intestinal injury.

Start Date30 Sep 2024

Sponsor / Collaborator

Xijing Hospital

100 Clinical Results associated with L-Glutamine

100 Translational Medicine associated with L-Glutamine

100 Patents (Medical) associated with L-Glutamine

6,344

Literatures (Medical) associated with L-Glutamine

01 Sep 2025·Neural Regeneration Research

Targeting harmful effects of non-excitatory amino acids as an alternative therapeutic strategy to reduce ischemic damage

Article

Author: Kirov, Sergei A. ; Carretero, Victoria Jiménez ; Hernández-Guijo, Jesús M. ; Álvarez-Merz, Iris ; Hernández-Campano, Jorge

The involvement of the excitatory amino acids glutamate and aspartate in cerebral ischemia and excitotoxicity is well-documented. Nevertheless, the role of non-excitatory amino acids in brain damage following a stroke or brain trauma remains largely understudied. The release of amino acids by necrotic cells in the ischemic core may contribute to the expansion of the penumbra. Our findings indicated that the reversible loss of field excitatory postsynaptic potentials caused by transient hypoxia became irreversible when exposed to a mixture of just four non-excitatory amino acids (L-alanine, glycine, L-glutamine, and L-serine) at their plasma concentrations. These amino acids induce swelling in the somas of neurons and astrocytes during hypoxia, along with permanent dendritic damage mediated by N-methyl-D-aspartate receptors. Blocking N-methyl-D-aspartate receptors prevented neuronal damage in the presence of these amino acids during hypoxia. It is likely that astroglial swelling caused by the accumulation of these amino acids via the alanine-serine-cysteine transporter 2 exchanger and system N transporters activates volume-regulated anion channels, leading to the release of excitotoxins and subsequent neuronal damage through N-methyl-D-aspartate receptor activation. Thus, previously unrecognized mechanisms involving non-excitatory amino acids may contribute to the progression and expansion of brain injury in neurological emergencies such as stroke and traumatic brain injury. Understanding these pathways could highlight new therapeutic targets to mitigate brain injury.

31 Dec 2024·Veterinary Quarterly

Insights of early feeding regime supplemented with glutamine and various levels of omega-3 in broiler chickens: growth performance, muscle building, antioxidant capacity, intestinal barriers health and defense against mixed Eimeria spp infection

Article

Author: Ezz-Eldin, Rasha M M ; El Sharkawy, Rasha B ; Ibrahim, Doaa ; Eldemery, Fatma ; Zayed, Shimaa ; Altuwaijri, Saleh ; Mulla, Zohair S ; Abd-Allah, Ehab M ; Abd El-Wahab, Reham A ; Youssef, Wessam ; Badr, Shereen ; Kishawy, Asmaa T Y ; Abdel Rahman, Mona Mohammed I

Early nutritional management approach greatly impacts broilers' performance and resistance against coccidiosis. The current study explored the impact of post-hatch feeding with a combination of glutamine (Glut) and different levels of omega-3 on broiler chickens' growth performance, muscle building, intestinal barrier, antioxidant ability and protection against avian coccidiosis. A total of six hundred Cobb 500 was divided into six groups: first group (fed basal diet and unchallenged (control) and challenged (negative control, NC) groups were fed a basal diet without additives, and the other groups were infected with Eimeria spp and supplemented with 1.5% Glut alone or with three different levels of omega-3 (0.25, 0.5 and 1%) during the starter period. Notable improvement in body weight gain was observed in the group which fed basal diet supplemented with glut and 1% omega 3 even after coccidia infection (increased by 25% compared challenged group) while feed conversion ratio was restored to control. Myogeneis was enhanced in the group supplemented with Glut and omega-3 (upregulation of myogenin, MyoD, mechanistic target of rapamycin kinase and insulin like growth factor-1 and downregulating of myostatin genes). Groups supplemented with Glut and higher levels of omega-3 highly expressed occluding, mucin-2, junctional Adhesion Molecule 2, b-defensin-1 and cathelicidins-2 genes. Group fed 1% Glut + omega-3 showed an increased total antioxidant capacity and glutathione peroxidase and super oxide dismutase enzymes activities with reduced levels of malondialdehyde, reactive oxygen species and H₂O₂. Post-infection, dietary Glut and 1% omega-3 increased intestinal interleukin-10 (IL) and secretory immunoglobulin-A and serum lysozyme, while decreased the elevated inflammatory mediators comprising interleukin IL-6, tumor necrosis factor-alpha, nitric oxide (NO) and inducible NO synthase. Fecal oocyst excretion and lesions score severity were lowered in the group fed 1% Glut and omega 3. Based on these findings, dietary Glut and omega-3 supplementation augmented restored overall broilers' performance after coccidial challenge.

31 Dec 2024·Redox Report

Glutamine sustains energy metabolism and alleviates liver injury in burn sepsis by promoting the assembly of mitochondrial HSP60-HSP10 complex via SIRT4 dependent protein deacetylation

Article

Author: Yang, Yongjun ; Lu, Yongling ; Peng, Xi ; Huang, Qianyin ; Fan, Shijun ; Chen, Qian ; Liu, Xin

Burns and burn sepsis, characterized by persistent and profound hypercatabolism, cause energy metabolism dysfunction that worsens organ injury and systemic disorders. Glutamine (Gln) is a key nutrient that remarkably replenishes energy metabolism in burn and sepsis patients, but its exact roles beyond substrate supply is unclear. In this study, we demonstrated that Gln alleviated liver injury by sustaining energy supply and restoring redox balance. Meanwhile, Gln also rescued the dysfunctional mitochondrial electron transport chain (ETC) complexes, improved ATP production, reduced oxidative stress, and protected hepatocytes from burn sepsis injury. Mechanistically, we revealed that Gln could activate SIRT4 by upregulating its protein synthesis and increasing the level of Nicotinamide adenine dinucleotide (NAD⁺), a co-enzyme that sustains the activity of SIRT4. This, in turn, reduced the acetylation of shock protein (HSP) 60 to facilitate the assembly of the HSP60-HSP10 complex, which maintains the activity of ETC complex II and III and thus sustain ATP generation and reduce reactive oxygen species release. Overall, our study uncovers a previously unknown pharmacological mechanism involving the regulation of HSP60-HSP10 assembly by which Gln recovers mitochondrial complex activity, sustains cellular energy metabolism and exerts a hepato-protective role in burn sepsis.

News (Medical) associated with L-Glutamine

25 Oct 2024

·www.prnewswire.com

KIND Announces FDA Granted Orphan Drug Designation (ODD) for AND017 in the Treatment of Sickle Cell Disease (SCD)

SAN FRANCISCO, Oct. 25, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to AND017 in the treatment of Sickle Cell Disease (SCD). AND017 is being developed to treat various anemia indications associated with diseases including non-dialysis dependent chronic kidney disease (NDD-CKD) and dialysis-dependent chronic kidney disease (DD-CKD). The results for AND017's phase 1 in healthy subjects and phase 2 clinical trials in treatment of anemia in NDD-CKD and anemia in DD-CKD are currently being presented at the annual meeting of American Society of Nephrology (ASN) Kidney Week in San Diego. The preclinical work supporting AND017's ODD in SCD will be presented in future scientific meeting and subsequently published in a scientific journal. Sickle Cell Disease (SCD) is a devasting genetic disease with US patient population around 120,000; SCD disproportionally affects Black and African Americans, comprising more than 98% of patients living with this disease. "The FDA's granting of ODD for AND017 underscores the urgent medical need for new therapies, particularly oral drugs to safely and effectively treat patients with SCD," said Dong Liu, Ph.D., Founder, Chairman, and CEO of Kind Pharmaceutical. "The granting of ODD also demonstrates the innovation capability and the vision of Kind Pharmaceutical." "Hydroxyurea and L-glutamine are the limited FDA-approved oral treatments for SCD, AND017 from Kind Pharmaceutical might not only provide a novel oral treatment with unique mechanism of action, but also an obvious better safety and efficacy profile." said Prof. Gang Huang at UT Health San Antonio, Kathryn Mays Johnson Distinguished Chair in Oncology, who is an expert in studies of hematology and various blood diseases, and involved in the preclinical studies of AND017 in SCD. "I am eager to see how a compound with such unbelievable preclinical safety and efficacy data will translate to real world SCD patients." FDA Orphan Drug Designation (ODD) is granted to a drug or biological product to prevent, diagnose or treat a rare disease or condition that affects fewer than 200,000 people in the United States. ODD qualifies KIND for incentives including tax credit for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after AND017's approval for treatment of Sickle Cell Disease (SCD). About Sickle Cell Disease (SCD) Sickle Cell Disease (SCD) affects around 120,000 patients in US and more than 8,000,000 worldwide. As a genetic disease with a single amino acid mutation in the β-globin of mature adult hemoglobin, the hemoglobin molecules of in the red blood cells (RBCs) of SCD patients are prone to aggregate in the tissue after the dissociation of oxygen molecules, which would cause the RBCs sickling in the blood stream and eventually lead to hemolysis and occlusion of capillaries; therefore the hallmarks of SCD are hemolytic anemia and vaso-occlusive crises (VOCs); and SCD causes multiorgan failure and premature death. About AND017 AND017 is a first-in-class hemoglobin elevating agent (HbEA) that targets multiple stages of the red blood cell (RBC) life cycle and is being developed to treat anemia associated with dialysis-dependent chronic kidney disease (DD-CKD), non-dialysis dependent chronic kidney disease (NDD-CKD), cancer-related anemia (CRA), myelodysplastic syndromes (MDS) anemia, sickle cell disease (SCD), and β-thalassemia. About Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC") KIND is a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers. The company's mission, "kind to human, humble to science, good to patients", drives its commitment to advancing current science to meet unmet medical need. KIND's lead clinical candidate, AND017, first-in-class hemoglobin elevating agent (HbEA), is being developed for treating anemia of various disorders, including dialysis dependent chronic kidney disease (DD-CKD) associated anemia, non-dialysis dependent (NDD) CKD associated anemia, cancer related anemia (CRA), myelodysplastic syndromes (MDS) anemia, sickle cell disease (SCD), and β-thalassemia. KIND's second clinical candidate, AND019, an orally available brain penetrant selective estrogen receptor degrader (SERD), is being developed to treat ER+/Her2- breast cancer. KIND is also developing promising disruptive next generation ADC technologies. For details, please visit . Contact: Dong Liu, PhD, Chairman and CEO of Kind Pharmaceutical Email: [email protected] Tel: 650-315 6151 SOURCE KInd Pharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultOrphan DrugPhase 2

25 Oct 2024

·www.biospace.com

KIND Announces FDA Granted Orphan Drug Designation (ODD) for AND017 in the Treatment of Sickle Cell Disease (SCD)

SAN FRANCISCO , Oct. 25, 2024 /PRNewswire/ -- Kind Pharmaceutical (“Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC”), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to AND017 in the treatment of Sickle Cell Disease (SCD). AND017 is being developed to treat various anemia indications associated with diseases including non-dialysis dependent chronic kidney disease (NDD-CKD) and dialysis-dependent chronic kidney disease (DD-CKD). The results for AND017’s phase 1 in healthy subjects and phase 2 clinical trials in treatment of anemia in NDD-CKD and anemia in DD-CKD are currently being presented at the annual meeting of American Society of Nephrology (ASN) Kidney Week in San Diego . The preclinical work supporting AND017’s ODD in SCD will be presented in future scientific meeting and subsequently published in a scientific journal. Sickle Cell Disease (SCD) is a devasting genetic disease with US patient population around 120,000; SCD disproportionally affects Black and African Americans, comprising more than 98% of patients living with this disease. “The FDA’s granting of ODD for AND017 underscores the urgent medical need for new therapies, particularly oral drugs to safely and effectively treat patients with SCD,” said Dong Liu , Ph.D., Founder, Chairman, and CEO of Kind Pharmaceutical. “The granting of ODD also demonstrates the innovation capability and the vision of Kind Pharmaceutical.” “Hydroxyurea and L-glutamine are the limited FDA-approved oral treatments for SCD, AND017 from Kind Pharmaceutical might not only provide a novel oral treatment with unique mechanism of action, but also an obvious better safety and efficacy profile.” said Prof. Gang Huang at UT Health San Antonio, Kathryn Mays Johnson Distinguished Chair in Oncology, who is an expert in studies of hematology and various blood diseases, and involved in the preclinical studies of AND017 in SCD. “I am eager to see how a compound with such unbelievable preclinical safety and efficacy data will translate to real world SCD patients.” FDA Orphan Drug Designation (ODD) is granted to a drug or biological product to prevent, diagnose or treat a rare disease or condition that affects fewer than 200,000 people in the United States . ODD qualifies KIND for incentives including tax credit for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after AND017’s approval for treatment of Sickle Cell Disease (SCD). About Sickle Cell Disease (SCD) Sickle Cell Disease (SCD) affects around 120,000 patients in US and more than 8,000,000 worldwide. As a genetic disease with a single amino acid mutation in the β-globin of mature adult hemoglobin, the hemoglobin molecules of in the red blood cells (RBCs) of SCD patients are prone to aggregate in the tissue after the dissociation of oxygen molecules, which would cause the RBCs sickling in the blood stream and eventually lead to hemolysis and occlusion of capillaries; therefore the hallmarks of SCD are hemolytic anemia and vaso-occlusive crises (VOCs); and SCD causes multiorgan failure and premature death. About AND017 AND017 is a first-in-class hemoglobin elevating agent (HbEA) that targets multiple stages of the red blood cell (RBC) life cycle and is being developed to treat anemia associated with dialysis-dependent chronic kidney disease (DD-CKD), non-dialysis dependent chronic kidney disease (NDD-CKD), cancer-related anemia (CRA), myelodysplastic syndromes (MDS) anemia, sickle cell disease (SCD), and β-thalassemia. About Kind Pharmaceutical (“Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC”) KIND is a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers. The company’s mission, “kind to human, humble to science, good to patients”, drives its commitment to advancing current science to meet unmet medical need. KIND’s lead clinical candidate, AND017, first-in-class hemoglobin elevating agent (HbEA), is being developed for treating anemia of various disorders, including dialysis dependent chronic kidney disease (DD-CKD) associated anemia, non-dialysis dependent (NDD) CKD associated anemia, cancer related anemia (CRA), myelodysplastic syndromes (MDS) anemia, sickle cell disease (SCD), and β-thalassemia. KIND’s second clinical candidate, AND019, an orally available brain penetrant selective estrogen receptor degrader (SERD), is being developed to treat ER+/Her2- breast cancer. KIND is also developing promising disruptive next generation ADC technologies. For details, please visit . Contact: Dong Liu , PhD, Chairman and CEO of Kind Pharmaceutical Email: liudong@kindpharmaceutical.com Tel: 650-315 6151 View original content: SOURCE KInd Pharmaceuticals

Clinical ResultOrphan DrugPhase 2

26 Sep 2024

·www.outsourcing-pharma.com

Pfizer withdraws sickle cell disease drug Oxbryta amid safety concerns

The withdrawal decision was prompted by clinical data indicating that the overall benefit of Oxbryta “no longer outweighs the risk” in its target patient population, the company said in a public release . Specifically, the trials outline an “imbalance” in vaso-occlusive crises and fatal events that the company will assess further. The move to stop clinical trials of the drug will last while Pfizer further reviews the available data and investigates the findings. Sickle cell disease is a genetic blood disorder where patients have a mutation in hemoglobin, a protein found in red blood cells. This leads the protein to clump together, causing cells to have a sickle shape that can block blood vessels and carry less oxygen, leading to acute pain and anemia. Oxbryta, whose generic name is voxelotor, is an oral small molecule drug that was first approved by the US Food and Drug Administration (FDA) for the treatment of sickle cell disease in 2019, with an EU approval granted in 2022. The drug is designed to make hemoglobin better at carrying oxygen and less prone to clumping together, making red blood cells more functional. The treatment was previously developed by the U.S. firm Global Blood Therapeutics before the company was snapped up by Pfizer for $5.4 billion in 2022 , and bagged Pfizer $328 million in revenues in 2023 . The big pharma company has notified regulators about the data and doesn’t expect the event to impact its full-year 2024 financial guidance. Nevertheless, the company’s stock price on the New York Stock Exchange slumped by more than 1% at the news yesterday (Wednesday 25th September). googletag.cmd.push(function () { googletag.display('text-ad1'); }); Emphasizing Pfizer’s focus on patient safety, chief medical officer and head of worldwide medical and safety, Aida Habtezion, said in the company release that the Pfizer’s “primary concern is for patients who suffer from SCD, which remains a very serious and difficult-to-treat disease with limited treatment options. We advise patients to contact their physicians to discuss alternative treatment while we continue to investigate the findings from our review of the data.” The global market for sickle cell disease was worth $2.25 billion in 2022 and is expected to grow by 20.1% per year to $9.84 billion by 2030. The main players in the market have included Pfizer with Oxbryta, Novartis with the antibody Adakveo (crizanlizumab) and Generex Biotechnology’s Emmaus Medical with Endari (L-glutamine). In 2017, Endari became the first branded drug for sickle cell disease in decades when it was greenlit by the U.S. FDA. Another driver for the sickle cell disease market is gene therapy, with the first cell-based gene therapies – Casgevy by Vertex Pharmaceuticals and Lyfgenia by Bluebird Bio – approved by the U.S. FDA in late 2023 .

Drug ApprovalGene Therapy

100 Deals associated with L-Glutamine

External Link

KEGG	Wiki	ATC	Drug Bank
D00015	L-Glutamine	A16AA03	DB00130

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia, Sickle Cell	US	Emmaus Medical, Inc.	07 Jul 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diverticulitis	Phase 3	US	Emmaus Medical, Inc.	31 Oct 2021
Diabetes Mellitus, Type 2	Phase 3	US	Emmaus Medical, Inc.	24 Jun 2019
Beta-Thalassemia	Phase 3	US	Emmaus Medical, Inc.	01 May 2010
Gastrointestinal Neoplasms	Phase 3	FR	Nestlé SA	01 Oct 2007
Anemia, Sickle Cell	Phase 3	TR	Impatients NV	-
Advanced Pancreatic Adenocarcinoma	Phase 1	US	Emmaus Medical, Inc.	13 May 2021
Pancreatic Ductal Adenocarcinoma	Phase 1	US	Emmaus Medical, Inc.	13 May 2021
Diverticulosis, Colonic	Phase 1	US	Emmaus Medical, Inc.	19 Jul 2019
Diverticulosis, Esophageal	Phase 1	US	Emmaus Medical, Inc.	19 Jul 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed	Not Applicable	MELAS Syndrome	9	High-dose oral glutamine supplementation	ddmdtktnle(txsrmsxxcl) = another patient was admitted for an epileptic status without stroke-like episode ytsconidxj (ublctixovv ) View more	-	05 Nov 2022
NCT01952847 (CTgov)	Phase 3	Neoplasms \| Mucositis \| Stomatitis \| Esophagitis	77	Questionnaires+Glutamine (Radiation Therapy to Esophagus Patient Group - Glutamine)	luqomldwte(kbbuquzrsy) = ewnzonrgve pmyfjoomkg (eyqqzgoxoi, vnglrpndhf - tzmbdixgrd) View more	-	15 Jun 2022
				Questionnaires (Radiation Therapy to Esophagus Patient Group - Placebo)	luqomldwte(kbbuquzrsy) = oamddrnpro pmyfjoomkg (eyqqzgoxoi, bzukoolfsk - hjzagfdsjv) View more
EHA2022	Phase 3	Anemia, Sickle Cell	19	L-glutamine	(avvnraapyn) = ltdtnwbqah qpshaehhnu (mnztrnlhnb ) View more	-	12 May 2022
NCT01048905 (CTgov)	Phase 2	Thalassemia \| Associated Pulmonary Arterial Hypertension \| Anemia, Sickle Cell	13	L-Glutamine	izbacnixne(upcqihlnnk) = rwkorwoxpu ngdicobtlm (asqgqbykwi, gqvrqfadlb - yfabqxaeou) View more	-	10 Jun 2021
NCT00586209 (CTgov)	Phase 2	Thalassemia \| Anemia, Sickle Cell	15	L-Glutamine (L-glutamine)	scpbjhvgyu(nlmwkldwfo) = pmwvmpfbxo goyeqrlhgp (udmonuseft, deqdyecsqa - uvsmwhzluv) View more	-	02 Feb 2021
				Placebo (Placebo)	scpbjhvgyu(nlmwkldwfo) = oshukzosil goyeqrlhgp (udmonuseft, jxgiyzimnl - ktfxhaanok) View more
NCT00125788 (CTgov)	Phase 2	Thalassemia \| Anemia, Sickle Cell	70	L-glutamine (Investigational Product)	clzhelfjqe(gkzxrenyzb) = xihsxbjdls pzpcxhbuua (zjznujytpm, jlbyadgunj - cyksjfwrox) View more	-	29 Jan 2021
				Placebo (Placebo)	clzhelfjqe(gkzxrenyzb) = iqnuwbnhne pzpcxhbuua (zjznujytpm, uryjtrsawn - hffgutocxl) View more
NCT01534663 (GLUTFISH-HF, CTgov)	Phase 2/3	Hydrops Fetalis \| Heart Failure	31	Placebo (Placebo)	fezqcgysxq(bbouryvwjo) = wrqdjprtbi kjheqjmtug (ltjdpoiihw, yepapdoazt - ehujorpsmy) View more	-	22 Dec 2020
				Glutamine (Glutamine/Fishoil)	fezqcgysxq(bbouryvwjo) = xwezmhhlyz kjheqjmtug (ltjdpoiihw, yyzbbzbrpf - fiehfnnzzn) View more
NCT01783522 (CTgov)	Phase 2	Drug intoxication \| Multiple Myeloma \| Peripheral Nervous System Diseases	9	quality-of-life assessment+glutamine (Arm I (Preventative Nutritional Supplementation))	akgbxrzbcv(reyvfyxirw) = tspogjvejo vjcrstklkb (obqiptqdfg, wkkskkoqum - mzuburmmxu) View more	-	22 Oct 2019
				placebo (Arm II (Placebo))	akgbxrzbcv(reyvfyxirw) = olomirtuuo vjcrstklkb (obqiptqdfg, opxlneyoym - tmxpnsazdf) View more
NCT01414244 (Pubmed \| Gut)	Phase 2	Irritable Bowel Syndrome	106	Glutamine (5g/t.i.d.)	zkwlsawpic(amuqtciufc) = imvvnumbee akpwgvxick (drfmrrcwue )	Positive	01 Jun 2019
NCT02012608 (CTgov)	Phase 2	Breast Cancer	14	Glutamine (Glutamine)	cxfrjnhhhh(tmupdjjoze) = abbvsbraza dpzbsnrhjj (octdgjlzch, vigzqhgvsq - wdgbdaljsy) View more	-	29 May 2019
				Placebo (Placebo)	cxfrjnhhhh(tmupdjjoze) = fdxgdhkohp dpzbsnrhjj (octdgjlzch, oumbgmmgth - htaczugein) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis